Why Tenet Healthcare (THC) Stock Is Falling Today

Tenet Healthcare (THC) is down 3.1% today. Here is some analysis on what might have caused this price movement.

Analysis: The catalyst appears to be caution ahead of Tenet’s October 29, 2026 earnings report rather than a fresh company-specific negative announcement. This could also be because investors are reacting to industry read-throughs on payer mix and exchange-related coverage pressure, an issue Tenet has already flagged as a headwind in its hospital business.

Details:

Tenet said on October 2 that it will release third-quarter 2026 results before the market opens on October 29, putting the stock in a typical pre-earnings setup where traders often reduce risk.

In its second-quarter release, Tenet posted strong results and raised its 2026 financial outlook, but it also said lower exchange admissions created an unfavorable payer-mix impact.

Another large hospital operator said on October 27 that more uninsured volume tied to lost exchange coverage hurt third-quarter profitability, which may have increased investor concern for the broader hospital group.

No major new Tenet press release or SEC filing appears to explain today’s drop directly, so the move looks more like earnings positioning and sector spillover than a response to a single headline.

Sources:

Tenet Healthcare, HCA Healthcare, SEC

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$THC Insider Trading Activity

$THC insiders have traded $THC stock on the open market 25 times in the past 6 months. Of those trades, 0 have been purchases and 25 have been sales.

Here’s a breakdown of recent trading of $THC stock by insiders over the last 6 months:

SAUMYA SUTARIA (CEO) has made 0 purchases and 5 sales selling 100,000 shares for an estimated $27,636,334.
LISA Y FOO (EVP, Chief Operating Officer) has made 0 purchases and 2 sales selling 34,000 shares for an estimated $8,971,980.
J ROBERT KERREY has made 0 purchases and 8 sales selling 17,648 shares for an estimated $4,151,250.
PAOLA M ARBOUR (EVP, Chief Information Officer) sold 10,878 shares for an estimated $2,653,144
RICHARD J MARK sold 10,000 shares for an estimated $2,634,200
TAMMY ROMO has made 0 purchases and 2 sales selling 7,422 shares for an estimated $1,952,221.
JAMES L BIERMAN sold 5,000 shares for an estimated $1,224,800
CHRISTOPHER S. LYNCH sold 3,837 shares for an estimated $934,079
NADJA WEST has made 0 purchases and 2 sales selling 4,152 shares for an estimated $830,187.
CECIL D HANEY sold 1,300 shares for an estimated $361,438
ROY BLUNT sold 600 shares for an estimated $157,608

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

$THC Hedge Fund Activity

We have seen 330 institutional investors add shares of $THC stock to their portfolio, and 353 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

FMR LLC removed 3,782,034 shares (-48.6%) from their portfolio in Q2 2026, for an estimated $707,542,920
LONE PINE CAPITAL LLC removed 2,258,717 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $422,560,776
WELLINGTON MANAGEMENT GROUP LLP removed 2,137,500 shares (-91.2%) from their portfolio in Q2 2026, for an estimated $399,883,500
D. E. SHAW & CO., INC. removed 1,159,115 shares (-97.4%) from their portfolio in Q2 2026, for an estimated $216,847,234
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP added 1,036,753 shares (+154.3%) to their portfolio in Q2 2026, for an estimated $193,955,751
MANNING & NAPIER ADVISORS LLC added 901,645 shares (+inf%) to their portfolio in Q2 2026, for an estimated $168,679,746
PENTWATER CAPITAL MANAGEMENT LP added 765,000 shares (+inf%) to their portfolio in Q2 2026, for an estimated $143,116,200

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$THC Price Targets

Multiple analysts have issued price targets for $THC recently. We have seen 8 analysts offer price targets for $THC in the last 6 months, with a median target of $234.5.

Here are some recent targets:

Andrew Mok from Barclays set a target price of $240.0 on 07/09/2026
Ryan Langston from TD Cowen set a target price of $233.0 on 06/22/2026
Michael Ha from Baird set a target price of $210.0 on 05/05/2026
Raj Kumar from Stephens & Co. set a target price of $260.0 on 05/04/2026
Stephen Baxter from Wells Fargo set a target price of $213.0 on 05/01/2026
Matthew Gillmor from Keybanc set a target price of $225.0 on 05/01/2026
Jason Cassorla from Guggenheim set a target price of $252.0 on 05/01/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.